{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320557349376.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmoa021812"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021812"}},{"identifier":{"@type":"NAID","@value":"30022558368"}}],"dc:title":[{"@value":"Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320557349382","@type":"Researcher","foaf:name":[{"@value":"Stephanos J. Hadziyannis"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349384","@type":"Researcher","foaf:name":[{"@value":"Nicolaos C. Tassopoulos"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349385","@type":"Researcher","foaf:name":[{"@value":"E. Jenny Heathcote"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349388","@type":"Researcher","foaf:name":[{"@value":"Ting-Tsung Chang"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349378","@type":"Researcher","foaf:name":[{"@value":"George Kitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349379","@type":"Researcher","foaf:name":[{"@value":"Mario Rizzetto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349380","@type":"Researcher","foaf:name":[{"@value":"Patrick Marcellin"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349386","@type":"Researcher","foaf:name":[{"@value":"Seng Gee Lim"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349376","@type":"Researcher","foaf:name":[{"@value":"Zachary Goodman"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349383","@type":"Researcher","foaf:name":[{"@value":"Michael S. Wulfsohn"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349381","@type":"Researcher","foaf:name":[{"@value":"Shelly Xiong"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349377","@type":"Researcher","foaf:name":[{"@value":"John Fry"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320557349387","@type":"Researcher","foaf:name":[{"@value":"Carol L. Brosgart"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2003-02-27","prism:volume":"348","prism:number":"9","prism:startingPage":"800","prism:endingPage":"807"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021812"}],"createdAt":"2003-02-26","modifiedAt":"2017-06-15","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714657048832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714965416192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617685285632","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"HBx increases EGFR expression by inhibiting miR129–5p function"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757191892480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140544000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical course and predictive factors of virological response in long‐term lamivudine plus adefovir dipivoxil combination therapy for lamivudine‐resistant chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140804864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567188226381568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"DHX9 regulates production of hepatitis B virus-derived circular RNA and viral protein levels"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593737164032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204788892288","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Forefront of the viral chronic hepatitis treatment. Treatment of the case for which the treatment plans can not be decided. 2. Treatment of the case which is negative in HBe antigen and repeats liver function abnormality."},{"@value":"ウイルス性慢性肝炎治療の最先端―治療方針に迷う症例に対する治療―２．ＨＢｅ抗原陰性，肝機能異常を繰り返す症例に対する治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792496896","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"慢性Ｂ型肝炎に対するラミブジン治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795529216","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of Fanconi's syndrome caused by long-term administration of adefovir by a patient with chronic hepatitis B"},{"@language":"ja","@value":"長期のアデホビル投与によりFanconi症候群を来したB型慢性肝炎の1例"},{"@value":"症例報告 長期のアデホビル投与によりFanconi症候群を来したB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク チョウキ ノ アデホビル トウヨ ニ ヨリ Fanconi ショウコウグン オ キタシタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204871665152","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Decompensated Lamivudine-resistant Hepatitis B Virus-related Cirrhosis Treated Successfully with Adefovir Dipivoxil Allowing Surgery for Hepatocellular Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204873592576","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Treatment with Adefovir of One Patient Whose Cryoglobulinemic Vasculitis Relapsed under Lamivudine Therapy and Who was Diagnosed to Have HBV Virologic Breakthrough with YMDD Mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205746563840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Recent Advances in Hepatitis B Research"},{"@language":"ja","@value":"わが国におけるB型肝炎研究の最近の動向"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679428284160","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A role of platelets in liver fibrosis"},{"@language":"ja","@value":"肝線維化における血小板の役割"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679767509376","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Staging of hepatitis B virus carriers based on HBV markers and cancer risk-A system to assist in the selection of appropriate antiviral treatment-"},{"@value":"ＨＢＶマーカーと発癌リスクよりみたＨＢＶキャリアのステージ分類―適切な抗ウイルス治療の選択に向けて―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771909888","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case report of successful therapy with tenofovir for a multi-drug resistant chronic hepatitis B patient complicated with malignant lymphoma"},{"@language":"ja","@value":"多剤耐性変異を認めた悪性リンパ腫合併Ｂ型慢性肝炎に対しテノフォビルが著効した一例"},{"@value":"症例報告 多剤耐性変異を認めた悪性リンパ腫合併B型慢性肝炎に対しテノフォビルが著効した一例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク タザイ タイセイ ヘンイ オ ミトメタ アクセイ リンパ シュ ガッペイ Bガタ マンセイ カンエン ニ タイシ テノフォビル ガ チョコウシタ イチレイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679846719360","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Overlap/Switch to Adefovir Monotherapy for Lamivudine-resistant Patients Who Responded to Combination Therapy: A Pilot Controlled Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679849678208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hypophosphatemic Osteomalacia Due to Drug-induced Fanconi's Syndrome Associated with Adefovir Dipivoxil Treatment for Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679850702592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713058047104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750573120896","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Combination therapy with lamivudine and HB vaccine on chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650385414656","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Liver transplantation for hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500083016576","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975317212928","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Appropriate use of interferon for treatment of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa021812"},{"@type":"CIA","@value":"30022558368"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.187_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.49.3342_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i23.2427_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.55.6301_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.35_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2491/jjsth.22.71_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.1016/j.bbrc.2020.06.018_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1698-18_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.3390/ijms23147878_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.1002/jmv.22025_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.1002/jmv.23564_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.46.6079_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.3851/imp3225_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.25104_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.1016/j.jcmgh.2021.07.013_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.14789/pjmj.55.443_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.53.1213_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.45.1816_references_DOI_RqDvT8qYUCrhbjFoRfapLWN28tu"}]}